Spica Therapeutics is pioneering Macrophage-Subset targeted therapies
Animab develops antibodies to tackle gastrointestinal pathogens in livestock.
Pleevi provides AI-driven smart charging solutions that optimize energy usage for electric vehicles.
"Swave’s HXR gigapixel technology will forever change the way we see and experience displayed still images, videos and live imaging."
"Swave’s HXR gigapixel technology will forever change the way we see and experience displayed still images, videos and live imaging."
"Swave’s HXR gigapixel technology will forever change the way we see and experience displayed still images, videos and live imaging."
Swave develops holographic eXtended reality technology to make virtual reality practically indistinguishable from the real world.
"Swave’s HXR gigapixel technology will forever change the way we see and experience displayed still images, videos and live imaging."
Tanai Therapeutics is developing a first-in-class oral therapeutic for obesity.
"Our goal at VoxelSensors is to seamlessly integrate the physical and digital worlds to a point level where they become indistinguishable."
"Our goal at VoxelSensors is to seamlessly integrate the physical and digital worlds to a point level where they become indistinguishable."
"Our goal at VoxelSensors is to seamlessly integrate the physical and digital worlds to a point level where they become indistinguishable."
eyeo develops breakthrough color-splitting photonics for ultra-compact, high-performance imaging
Rainbow Crops combines multiplex genome editing and precision breeding to develop climate-resilient crop varieties
moveUP develops personalized remote digital care for patients undergoing surgery and other interventions.
Aloxy’s Internet of Things technology is enabling the petrochemical industry to innovate.
MRM Health is developing a novel type of therapeutics based on beneficial intestinal bacteria.
Blue Foot provides water-intensive industries with the technology to reuse water.
"Our technology has the potential to enhance the therapeutic effectiveness of cell-based therapies and make them more affordable.”
"Our technology has the potential to enhance the therapeutic effectiveness of cell-based therapies and make them more affordable.”
"Our technology has the potential to enhance the therapeutic effectiveness of cell-based therapies and make them more affordable.”
AmphiStar offers a portfolio of locally sourced biosurfactants to companies seeking to develop sustainable, performant & affordable products
Flindr aims to restore a patient’s impaired immune response to cancer
Qbic fund is a seed and early-stage venture capital fund, supporting spin-offs or start-ups that valorize research from Qbic's knowledge partners.
A knowledge partner spin-off, i.e. a company that was founded based on technological innovations originating at Qbic's partner universities, research institutes or hospitals.
A start-up linked to a knowledge partner, i.e. a company with a strong R&D collaboration with one of Qbic's knowledge partners. This collaboration can be structured through joint development contracts, clinical studies, IP license agreements, etc.
